Catherine Lomen-Hoerth, MD, PhD

Neurologist and director of the ALS Center

Dr. Catherine Lomen-Hoerth — a specialist in treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease — is director of the ALS Center at UCSF Medical Center. She is particularly interested in research involving electrophysiological and genetic predictors in ALS. Patients at the center have the opportunity to participate in research projects or clinical trials to test new treatments. Lomen-Hoerth also is interested in the overlap of ALS and frontotemporal dementia, a related neurodegenerative disease. She is certified by the American Board of Psychiatry and Neurology and is a member of the Bay Area chapter of the Amyotrophic Lateral Sclerosis Association.

Lomen-Hoerth earned a medical degree and a Ph.D. at Stanford University School of Medicine in neurosciences. At UCSF, she served as chief resident in neurology and completed a fellowship in electromyography and neuromuscular disorders. Her bachelor's degree is in biochemistry from the University of Arizona. Lomen-Hoerth is a professor in residence in neurology at UCSF.

Clinics

Neuropathy Center
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2273
Fax: (415) 353-2898

Hours: Monday and Tuesday
9 a.m. – 4 p.m.

Conditions & Treatments

Board Certification

Neurology, American Board of Psychiatry and Neurology

Academic Title

Professor

More about Catherine Lomen-Hoerth

Education

Stanford University School of Medicine, Neurosciences-PhD Program
Stanford University School of Medicine 1994

Residencies

UCSF Medical Center, Neurology 1998

Fellowships

UCSF Medical Center, EMG/Neurophysiology 1999

Selected Research and Publications

  1. Marzec NS, Nelson C, Waldron PR, Blackburn BG, Hosain S, Greenhow T, Green GM, Lomen-Hoerth C, Golden M, Mead PS. Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease - United States. MMWR Morb Mortal Wkly Rep. 2017 Jun 16; 66(23):607-609.
  2. Bock M, Duong YN, Kim A, Allen I, Murphy J, Lomen-Hoerth C. Cognitive-behavioral changes in amyotrophic lateral sclerosis: Screening prevalence and impact on patients and caregivers. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug; 17(5-6):366-73.
  3. Fournier CN, Murphy A, Loci L, Mitsumoto H, Lomen-Hoerth C, Kisanuki Y, Simmons Z, Maragakis NJ, McVey AL, Al-Lahham T, Heiman-Patterson TD, Andrews J, McDonnell E, Cudkowicz M, Atassi N. Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population. J Clin Neuromuscul Dis. 2016 Mar; 17(3):99-105.
  4. Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology. 2016 Mar 01; 86(9):813-20.
  5. Boylan K, Levine T, Lomen-Hoerth C, Lyon M, Maginnis K, Callas P, Gaspari C, Tandan R. Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters. Amyotroph Lateral Scler Frontotemporal Degener. 2015; 17(1-2):119-27.
  6. Simon NG, Ralph JW, Lomen-Hoerth C, Poncelet AN, Vucic S, Kiernan MC, Kliot M. Quantitative ultrasound of denervated hand muscles. Muscle Nerve. 2015 Aug; 52(2):221-30.
  7. Malik R, Lui A, Lomen-Hoerth C. Amyotrophic lateral sclerosis. Semin Neurol. 2014 Nov; 34(5):534-41.
  8. Simon NG, Lomen-Hoerth C, Kiernan MC. Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle Nerve. 2014 Dec; 50(6):894-9.
  9. Murphy J, Ahmed F, Lomen-Hoerth C. The UCSF screening exam effectively screens cognitive and behavioral impairment in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar; 16(1-2):24-30.
  10. Simon NG, Turner MR, Vucic S, Al-Chalabi A, Shefner J, Lomen-Hoerth C, Kiernan MC. Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol. 2014 Nov; 76(5):643-57.
  11. Pattee GL, Wymer JP, Lomen-Hoerth C, Appel SH, Formella AE, Pope LE. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Curr Med Res Opin. 2014 Nov; 30(11):2255-65.
  12. Rabkin J, Ogino M, Goetz R, McElhiney M, Hupf J, Heitzman D, Heiman-Patterson T, Miller R, Katz J, Lomen-Hoerth C, Imai T, Atsuta N, Morita M, Tateishi T, Matsumura T, Mitsumoto H. Japanese and American ALS patient preferences regarding TIV (tracheostomy with invasive ventilation): a cross-national survey. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun; 15(3-4):185-91.
  13. Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun; 15(3-4):192-203.
  14. Simon NG, Ayer G, Lomen-Hoerth C. Is IVIg therapy warranted in progressive lower motor neuron syndromes without conduction block? Neurology. 2013 Dec 10; 81(24):2116-20.
  15. Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Josephs KA, Knopman DS, White CL, Caselli R, Mackenzie IR, Miller BL, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, Barcikowska M, Younkin SG, Petersen RC, Ertekin-Taner N, Uitti RJ, Meschia JF, Boylan KB, Boeve BF, Graff-Radford NR, Wszolek ZK, Dickson DW, Rademakers R, Ross OA. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener. 2013 Jun 21; 8:19.
  16. Lopez J, Lomen-Hoerth C, Deutsch GK, Kerchner GA, Koshy A. Influenza-associated global amnesia and hippocampal imaging abnormality. Neurocase. 2014 Aug; 20(4):446-51.
  17. ALS Untangled No. 20: the Deanna protocol. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May; 14(4):319-23.
  18. Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, Floeter MK, Henderson C, Lomen-Hoerth C, Macklis JD, McCluskey L, Mitsumoto H, Przedborski S, Rothstein J, Trojanowski JQ, van den Berg LH, Ringel S. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May; 14 Suppl 1:5-18.
  19. Takada LT, Pimentel ML, Dejesus-Hernandez M, Fong JC, Yokoyama JS, Karydas A, Thibodeau MP, Rutherford NJ, Baker MC, Lomen-Hoerth C, Rademakers R, Miller BL. Frontotemporal dementia in a Brazilian kindred with the c9orf72 mutation. Arch Neurol. 2012 Sep; 69(9):1149-53.
  20. Rutherford NJ, Heckman MG, Dejesus-Hernandez M, Baker MC, Soto-Ortolaza AI, Rayaprolu S, Stewart H, Finger E, Volkening K, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Knopman DS, Kretzschmar HA, Neumann M, Caselli RJ, White CL, Mackenzie IR, Petersen RC, Strong MJ, Miller BL, Boeve BF, Uitti RJ, Boylan KB, Wszolek ZK, Graff-Radford NR, Dickson DW, Ross OA, Rademakers R. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging. 2012 Dec; 33(12):2950.e5-7.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.